As of 2025-10-30, the Relative Valuation of Urogen Pharma Ltd (URGN) is (33.16) USD. This relative valuation is based on P/E multiples. With the latest stock price at 19.78 USD, the upside of Urogen Pharma Ltd based on Relative Valuation is -267.7%.
The range of the Relative Valuation is (14.87) - (50.05) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 4.3x - 14.9x | 9.6x |
| Forward P/E multiples | 4.4x - 16.0x | 10.2x |
| Fair Price | (14.87) - (50.05) | (33.16) |
| Upside | -175.2% - -353.0% | -267.7% |
| Date | P/E |
| 2025-10-28 | -6.08 |
| 2025-10-27 | -6.22 |
| 2025-10-24 | -5.66 |
| 2025-10-23 | -5.17 |
| 2025-10-22 | -5.27 |
| 2025-10-21 | -5.42 |
| 2025-10-20 | -5.37 |
| 2025-10-17 | -5.06 |
| 2025-10-16 | -5.05 |
| 2025-10-15 | -5.16 |
| 2025-10-14 | -4.97 |
| 2025-10-13 | -5.00 |
| 2025-10-10 | -4.98 |
| 2025-10-09 | -4.90 |
| 2025-10-08 | -5.17 |
| 2025-10-07 | -5.03 |
| 2025-10-06 | -5.09 |
| 2025-10-03 | -5.19 |
| 2025-10-02 | -5.10 |
| 2025-10-01 | -5.32 |
| 2025-09-30 | -5.96 |
| 2025-09-29 | -5.71 |
| 2025-09-26 | -5.47 |
| 2025-09-25 | -5.15 |
| 2025-09-24 | -5.37 |
| 2025-09-23 | -5.34 |
| 2025-09-22 | -5.37 |
| 2025-09-19 | -5.36 |
| 2025-09-18 | -5.63 |
| 2025-09-17 | -5.40 |
| 2025-09-16 | -5.39 |
| 2025-09-15 | -5.39 |
| 2025-09-12 | -5.61 |
| 2025-09-11 | -5.75 |
| 2025-09-10 | -5.70 |
| 2025-09-09 | -6.18 |
| 2025-09-08 | -6.39 |
| 2025-09-05 | -5.64 |
| 2025-09-04 | -5.61 |
| 2025-09-03 | -5.78 |
| 2025-09-02 | -5.83 |
| 2025-08-29 | -5.81 |
| 2025-08-28 | -5.74 |
| 2025-08-27 | -5.83 |
| 2025-08-26 | -5.82 |
| 2025-08-25 | -5.52 |
| 2025-08-22 | -5.80 |
| 2025-08-21 | -5.90 |
| 2025-08-20 | -5.76 |
| 2025-08-19 | -5.65 |